T1	p 335 357	healthy young subjects
T2	p 443 461	of 8 subjects each
T3	p 634 641	treated
T4	p 651 665	completing the
T5	p 1544 1545	.
T6	p 1598 1606	subjects
T7	i 71 88	cholesteryl ester
T8	i 98 105	protein
T9	i 138 149	torcetrapib
T10	i 215 222	protein
T11	i 230 266	) inhibitor torcetrapib ( CP-529,414
T12	i 481 488	placebo
T13	i 491 513	n=2 ) or torcetrapib (
T14	i 559 565	120 mg
T15	i 572 577	daily
T16	i 738 742	nM )
T17	i 812 813	)
T18	i 1187 1201	Apolipoprotein
T19	i 1292 1294	mg
T20	i 1307 1320	. Cholesteryl
T21	o 6 38	Raising high-density lipoprotein
T22	o 272 331	raise high-density lipoprotein cholesterol ( HDL-C ) levels
T23	o 592 603	Torcetrapib
T24	o 608 622	well tolerated
T25	o 693 711	plasma drug levels
T26	o 833 837	CETP
T27	o 903 918	CETP inhibition
T28	o 974 982	of HDL-C
T29	o 1001 1025	Total plasma cholesterol
T30	o 1081 1089	nonHDL-C
T31	o 1129 1164	low-density lipoprotein cholesterol
T32	o 1187 1205	Apolipoprotein A-I
T33	o 1210 1211	E
T34	o 1261 1265	apoB
T35	o 1345 1361	and triglyceride
T36	o 1379 1401	nonHDL plasma fraction
T37	o 1442 1447	HDL .
T38	o 1551 1555	work
T39	o 1689 1704	atherosclerosis